Bevacizumab in the treatment of ovarian cancer

Ramez N Eskander1, Leslie M Randall21Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of California Irvine Medical Center, Orange, CA, USA; 2Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of California, Irvine, Orange, CA, U...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Ramez N Eskander, Leslie M Randall
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2011
Materias:	Medicine (General) R5-920
Acceso en línea:	https://doaj.org/article/eaf2adb7d17f4ca08eb11d5ecfccd55d
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:eaf2adb7d17f4ca08eb11d5ecfccd55d
record_format	dspace
spelling	oai:doaj.org-article:eaf2adb7d17f4ca08eb11d5ecfccd55d2021-12-02T03:17:04ZBevacizumab in the treatment of ovarian cancer1177-54751177-5491https://doaj.org/article/eaf2adb7d17f4ca08eb11d5ecfccd55d2011-01-01T00:00:00Zhttp://www.dovepress.com/bevacizumab-in-the-treatment-of-ovarian-cancer-a6042https://doaj.org/toc/1177-5475https://doaj.org/toc/1177-5491Ramez N Eskander1, Leslie M Randall21Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of California Irvine Medical Center, Orange, CA, USA; 2Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of California, Irvine, Orange, CA, USAAbstract: Despite advances in surgical cytoreduction and cytotoxic chemotherapy, ovarian cancer continues to be the leading cause of death in women with gynecologic malignancy. Our understanding of the treatment of ovarian cancer was revolutionized with the discovery of platinum- and taxane-based adjuvant chemotherapy regimens. Since that time however, overall survival has been stable. Given the above, an emphasis has been placed on exploring alternative therapeutics. Recent research efforts have improved our understanding of the molecular biology of ovarian cancer and novel targeted treatment strategies have emerged. The most studied of these agents has been the monoclonal anti-vascular endothelial growth factor antibody bevacizumab. The purpose of this review is to discuss management issues related to the treatment of ovarian cancer, with a focus on the utilization of bevacizumab, summarizing applicable clinical trials, its potential benefits, and reported adverse events.Keywords: bevacizumab, ovarian cancer, molecular targeted therapy, VEGF, angiogenesis Ramez N EskanderLeslie M RandallDove Medical PressarticleMedicine (General)R5-920ENBiologics: Targets & Therapy, Vol 2011, Iss default, Pp 1-5 (2011)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine (General) R5-920
spellingShingle	Medicine (General) R5-920 Ramez N Eskander Leslie M Randall Bevacizumab in the treatment of ovarian cancer
description	Ramez N Eskander1, Leslie M Randall21Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of California Irvine Medical Center, Orange, CA, USA; 2Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of California, Irvine, Orange, CA, USAAbstract: Despite advances in surgical cytoreduction and cytotoxic chemotherapy, ovarian cancer continues to be the leading cause of death in women with gynecologic malignancy. Our understanding of the treatment of ovarian cancer was revolutionized with the discovery of platinum- and taxane-based adjuvant chemotherapy regimens. Since that time however, overall survival has been stable. Given the above, an emphasis has been placed on exploring alternative therapeutics. Recent research efforts have improved our understanding of the molecular biology of ovarian cancer and novel targeted treatment strategies have emerged. The most studied of these agents has been the monoclonal anti-vascular endothelial growth factor antibody bevacizumab. The purpose of this review is to discuss management issues related to the treatment of ovarian cancer, with a focus on the utilization of bevacizumab, summarizing applicable clinical trials, its potential benefits, and reported adverse events.Keywords: bevacizumab, ovarian cancer, molecular targeted therapy, VEGF, angiogenesis
format	article
author	Ramez N Eskander Leslie M Randall
author_facet	Ramez N Eskander Leslie M Randall
author_sort	Ramez N Eskander
title	Bevacizumab in the treatment of ovarian cancer
title_short	Bevacizumab in the treatment of ovarian cancer
title_full	Bevacizumab in the treatment of ovarian cancer
title_fullStr	Bevacizumab in the treatment of ovarian cancer
title_full_unstemmed	Bevacizumab in the treatment of ovarian cancer
title_sort	bevacizumab in the treatment of ovarian cancer
publisher	Dove Medical Press
publishDate	2011
url	https://doaj.org/article/eaf2adb7d17f4ca08eb11d5ecfccd55d
work_keys_str_mv	AT ramezneskander bevacizumabinthetreatmentofovariancancer AT lesliemrandall bevacizumabinthetreatmentofovariancancer
_version_	1718401894830833664

Bevacizumab in the treatment of ovarian cancer

Ejemplares similares